Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

"Our alliance with Luminis Partners is an important component of our broader international focus to provide clients with strategic opportunities,” said Mark Van Lith, CEO of Guggenheim Securities. "We ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The $6.1 million artwork by Maurizio Cattelan was stolen from the Blenheim Palace in England in September 2019.

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...